- $1.77bn
- $1.24bn
- $68.56m
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO
Vir Biotechnology, Inc. reports results for the quarter ended June 30 - Earnings Summary
Vir Biotechnology Q2 revenue up, beats estimates on Astellas payment
Brief: Vir Biotechnology Q2 EPS USD 0.48
Vir Biotechnology Inc expected to post earnings of 33 cents a share - Earnings Preview
Brief: Vir Biotechnology To Present Complete Week 96 Data From Mid Stage Solstice Clinical Trial
Vir Biotechnology Q1 net loss widens
Brief: Vir Biotechnology Appoints Marianne De Backer As President In Addition To CEO On March 4, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Enovis, Cheniere, Packaging Corp of America
U.S. STOCKS ON THE MOVE-Qnity, J.M. Smucker, Vistra
U.S. STOCKS ON THE MOVE-Nvidia, Snowflake, Nutanix
Vir Biotech drops after $150 mln stock sale
Brief: Vir Biotechnology Announces Pricing Of Public Offering Of Common Stock At $8.50 Per Share
Vir Biotech soars again after prostate cancer drug collaboration with Astellas
Vir Biotech slips after unveiling $200 mln stock offering plans
U.S. STOCKS ON THE MOVE-Domino's Pizza, FactSet, IBM